With our extensive experience in developing gastrointestinal disease models, such as IBD preclinical, Emesis & Nausea, IBS, Gastric motility, our Gastroenterology (GI) department made Syncrosome one of the leaders in GI pathologies in the Contract Research Organization’s world. Indeed, our first disease models as a non-clinical CRO were developed in this therapeutic area.
In addition to our knowledge of animal models and in histological biomarkers, we were able to provide new answers to our customers needs with the use of cellular inflammation biomarkers, which provides complementary responses in models like IBD preclinical (MPO activity, ELISA, Cytokines, etc…) and the development of new techniques. Our disease models (guinea pigs, piglets, ferrets, rats or mice depending on the pathology) are fitted for testing disease-modifying drug or compounds acting on symptomatic effects. Depending on your needs, it is possible to perform classical, Per Os, Intravenous (IV), Intraperitoneal (IP) or Intrarectal administration.